ArticleBreast cancer research and treatment2017
Patterns and predictors of first and subsequent recurrence in women with early breast cancer.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Reassessing the Role of Regular Physical Examination in Post-treatment Breast Cancer Surveillance.Annals of surgical oncology · 2026Article
- External validation of a data-driven algorithm to identify breast cancer recurrences from administrative healthcare data.Breast (Edinburgh, Scotland) · 2026Article
- Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT.Annals of nuclear medicine · 2026Article
- Article
- The authors respond to feedback onFrontiers in oncology · 2026Article
- Assessing the recurrence rate in locally advanced Luminal A patients compared to triple-negative patients in Shahid Rahimi Hospital Khorramabad in 2022: a cross-sectional study.Annals of medicine and surgery (2012) · 2025Article
- Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors.Cancer research · 2025Article
- Machine learning prediction of breast cancer local recurrence localization, and distant metastasis after local recurrences.Scientific reports · 2025Article
- Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.Breast cancer research and treatment · 2025Article
- Article
- Automatic segmentation-based multi-modal radiomics analysis of US and MRI for predicting disease-free survival of breast cancer: a multicenter study.Breast cancer research : BCR · 2024Article
- AI Survival Prediction Modeling: The Importance of Considering Treatments and Changes in Health Status over Time.Cancers · 2024Article
- Risk of first recurrence after treatment in a population-based cohort of young women with breast cancer.Breast cancer research and treatment · 2024Article
- Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.Breast cancer research and treatment · 2024Article
- Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Development and validation of a nomogram for predicting rapid relapse in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.Frontiers in cell and developmental biology · 2024Article
- The impact of the HER2-low status on conditional survival in patients with breast cancer.Therapeutic advances in medical oncology · 2024Article
- Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.Breast cancer research and treatment · 2023Article
- Regularly scheduled physical examinations and the detection of breast cancer recurrences.Breast (Edinburgh, Scotland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLittle is known about the occurrence, timing and prognostic factors for first and also subsequent local (LR), regional (RR) or distant (DM) breast cancer recurrence. As current follow-up is still consensus-based, more information on the patterns and predictors of subsequent recurrences can inform more personalized follow-up decisions.
methodsWomen diagnosed with stage I-III invasive breast cancer who were treated with curative intent were selected from the Netherlands Cancer Registry (N = 9342). Extended Cox regression was used to model the hazard of recurrence over ten years of follow-up for not only site-specific first, but also subsequent recurrences after LR or RR.
resultsIn total, 362 patients had LR, 148 RR and 1343 DM as first recurrence. The risk of first recurrence was highest during the second year post-diagnosis (3.9%; 95% CI 3.5-4.3) with similar patterns for LR, RR and DM. Young age (<40), tumour size >2 cm, tumour grade II/III, positive lymph nodes, multifocality and no chemotherapy were prognostic factors for first recurrence. The risk of developing a second recurrence after LR or RR (N = 176) was significantly higher after RR than after LR (50 vs 29%; p < 0.001). After a second LR or RR, more than half of the women were diagnosed with a third recurrence.
conclusionsAlthough the risk of subsequent recurrence is high, absolute incidence remains low. Also, almost half the second recurrences are detected in the first year after previous recurrence and more than 80% are DM. This suggests that more intensive follow-up for early detection subsequent recurrence is not likely to be (cost-)effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.